This company listing is no longer active
Genocea Biosciences Beheer
Beheer criteriumcontroles 2/4
Belangrijke informatie
Chip Clark
Algemeen directeur
US$3.8m
Totale compensatie
| Percentage CEO-salaris | 15.2% |
| Dienstverband CEO | 11.6yrs |
| Eigendom CEO | 0.05% |
| Management gemiddelde ambtstermijn | 6.6yrs |
| Gemiddelde ambtstermijn bestuur | 8yrs |
Recente managementupdates
Recent updates
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2022 | n/a | n/a | -US$37m |
| Dec 31 2021 | US$4m | US$571k | -US$33m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$1m | US$551k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$41m |
| Mar 31 2020 | n/a | n/a | -US$36m |
| Dec 31 2019 | US$1m | US$533k | -US$39m |
| Sep 30 2019 | n/a | n/a | -US$29m |
| Jun 30 2019 | n/a | n/a | -US$30m |
| Mar 31 2019 | n/a | n/a | -US$27m |
| Dec 31 2018 | US$1m | US$515k | -US$28m |
| Sep 30 2018 | n/a | n/a | -US$39m |
| Jun 30 2018 | n/a | n/a | -US$48m |
| Mar 31 2018 | n/a | n/a | -US$59m |
| Dec 31 2017 | US$2m | US$493k | -US$57m |
| Sep 30 2017 | n/a | n/a | -US$62m |
| Jun 30 2017 | n/a | n/a | -US$58m |
| Mar 31 2017 | n/a | n/a | -US$54m |
| Dec 31 2016 | US$1m | US$455k | -US$50m |
| Sep 30 2016 | n/a | n/a | -US$44m |
| Jun 30 2016 | n/a | n/a | -US$41m |
| Mar 31 2016 | n/a | n/a | -US$40m |
| Dec 31 2015 | US$2m | US$427k | -US$42m |
Compensatie versus markt: De totale vergoeding ($USD 3.75M ) Chip } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.14K ).
Compensatie versus inkomsten: De vergoeding van Chip is gestegen terwijl het bedrijf verliesgevend is.
CEO
Chip Clark (53 yo)
11.6yrs
Tenure
US$3,750,857
Compensatie
Mr. William D. Clark, M.B.A., also known as Chip, has been an Independent Director at iBio, Inc. since August 26, 2021. He has been the Director, Chief Executive Officer and President at Genocea Bioscience...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 11.6yrs | US$3.75m | 0.048% € 314.6 | |
| Chief Scientific Officer | 6.6yrs | US$1.27m | 0.00087% € 5.7 | |
| CFO & Secretary | 3.5yrs | geen gegevens | 0.00051% € 3.3 |
6.6yrs
Gemiddelde duur
50yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van GBI1 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 11.6yrs | US$3.75m | 0.048% € 314.6 | |
| Independent Chairman of the Board | 8yrs | US$120.98k | 0% € 0 | |
| Independent Director | 7.6yrs | US$78.48k | 0% € 0 | |
| Independent Director | 9.5yrs | US$75.88k | 0.0066% € 43.3 | |
| Independent Chairman of Scientific Advisory Board & Director | 15.7yrs | US$66.98k | 0.00043% € 2.8 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | less than a year | US$61.50k | 0% € 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | less than a year | geen gegevens | 0% € 0 |
8.0yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GBI1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).